Clinerion Partners with Alpha MD to Fast Track Innovative Treatments in India
Clinerion is partnering with Alpha MD to expand patient treatment options in India. Indian patients may be matched with international research studies by bringing Indian healthcare organizations onto the Patient Network Explorer platform.
Alpha MD is a global clinical research and technology consultancy that provides end-to-end solutions to healthcare partners.
With this partnership, patients in India will gain better access to clinical care as the Patient Network Explorer draws international clinical studies to the country, directly to the patients who will benefit most from participation in trials. Patients will also benefit from the efficiencies created in the clinical research process by Patient Network Explorer which contribute to getting drugs faster to market. Patient Network Explorer’s efficiencies include accelerating study protocol development, identifying suitable trial sites, and speeding up patient search and identification for trial enrollment.
"We all are aware that identifying eligible patients for a trial is a long and costly process,” says Dr. Sanobar Parkar, Global Head Life Sciences, Alpha MD. “Many approvals or new drug launches in the market are delayed due to slow recruitment, thus costing a lot of money to sponsors. In addition, even patients who can benefit from participation in a clinical trial, especially in the oncology field, miss the opportunity due to lack of awareness of available study protocols among treating physicians. As a life science lead and a physician, I feel both these requirements are successfully met by the HIPAA and GDPR compliant Clinerion platform. By being part of this network, hospitals and patients in India will have access to global trials. This is necessary in making all alternatives available to patients and this will also eventually help in bringing new medicines to the Indian market and sooner.”
“We are eager to support the clinical care of patients in India by leveraging the benefits of Clinerion’s Patient Network Explorer,” says Ian Rentsch, Clinerion CEO. “With their strong presence in India, Alpha MD is well-placed to help us develop our site network there.”
For further details go to theDigital Health Conclave 2019 website www.swissnexindia.org/event/digital-health-conclave-2019
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
